Prosecution Insights
Prosecution Insights
Tech Center 3900 • Art Units: 1612 1631 1638 1657 1699 3991
This examiner grants 57% of resolved cases
Eric Jason Rogers has resolved 108 cases in Art Unit 1612 within Tech Center 3900. His allowance rate pct is 57.4, which is near the middle of the spectrum for patent examiners. The median days to allowance is 1426, indicating that applicants should prepare for a multi-year prosecution process. These 108 resolved cases establish a clear baseline for examiner behavior.
The data shows that interviews are a helpful tool, providing an interview lift pct of 32.6. This lift can be used to improve the 57.4 percent baseline allowance rate significantly. Given the 108 resolved cases, practitioners have a sufficient data set to conclude that interviews are a valuable investment of time and resources. The 32.6 percent lift suggests that verbal advocacy is often necessary to overcome rejections during the 1426-day median prosecution period.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17323715 | GENERATION OF HOXA-EXPRESSING HEMOGENIC ENDOTHELIUM WITH ENHANCED T CELL POTENTIAL FROM HPSCS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17783473 | USE OF POLYVINYL ALCOHOL FOR CELL CULTURE OF IMMUNE CELLS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17609957 | INDUCED HUMAN COLITIC ORGANOIDS | Final Rejection | The Cleveland Clinic Foundation |
| 17924040 | METHODS AND COMPOSITIONS FOR MAKING AND USING ENDOCARDIAL CELLS | Non-Final OA | University Health Network |
| 18573954 | STRUCTURALLY COMPLETE ORGANOIDS | Non-Final OA | Children's Hospital Medical Center |
| 17599028 | USE OF ONCOLYTIC VIRUSES IN THE NEOADJUVANT THERAPY OF CANCER | Non-Final OA | AMGEN INC. |
| 18262674 | TREATMENT FOR HSV-1 USING A MEGANUCLEASE | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18684884 | PEPTIDE AND GELATIN HYBRID HYDROGELS AS ECONOMICAL ALTERNATIVES TO COMMON BASEMENT-MEMBRANE MATRICES | Non-Final OA | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 17429391 | GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES | Final Rejection | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17783463 | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 | Final Rejection | MEDIMMUNE, LLC |
| 17292296 | USE OF ECM1 GENE-KNOCKOUT MOUSE IN SCREENING OF ANTI-HEPATIC FIBROSIS DRUG | Non-Final OA | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES |
| 18584830 | FUNCTIONAL POROSOME MANIPULATION | Final Rejection | Porosome Therapeutics, Inc. |
| 18446111 | FUNCTIONAL POROSOME MANIPULATION | Non-Final OA | Porosome Therapeutics, Inc. |
| 17050085 | METHOD FOR EXPANDING HUMAN DC CELL AND HUMAN DC CELL RESOURCE LIBRARY | Non-Final OA | Celartics Biopharma Co., Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy